In this work, we investigate the relationship of an individual’s estimated timing of progression of AD imaging biomarkers, amyloid and tau PET, and CVD imaging biomarkers, WMH and FA, via an AFT model. This evidence concerns the gene MAPT and Alzheimer disease.